 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CHICAGO, IL / ACCESSWIRE / November 17, 2023 / More than 300,000 people are diagnosed with brain cancer across the globe each year. Glioblastoma represents the majority of these cases in the U.S...

MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer

New results from a targeted therapy and immuno-oncology company show the promising potential efficacy of one of its first-in-class treatments.CHICAGO, IL / ACCESSWIRE / October 31, 2023 / MAIA...

MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer

CHICAGO, IL / ACCESSWIRE / October 17, 2023 / Diffuse Intrinsic Pontine Glioma (DIPG) is among the most aggressive brain tumors affecting the central nervous system in children. Radiotherapy, the...

MAIA Biotechnology's THIO Emerges As Potential Breakthrough In Pediatric Brain Cancer Therapy

MAIA Biotechnology, Inc. (NYSE: MAIA) (MAIA or the Company), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of an underwritten public offering of 2,222,200 shares of its common stock at a public offering price of $2.25 per...

MAIA Biotechnology, Inc. Announces Pricing of Public Offering

MAIA Biotechnology, Inc., (NYSE: MAIA) (MAIA, the Company), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the full year ended December 31, 2022, and provided a corporate update. We are very pleased with the progress...

MAIA Biotechnology Reports Full Year 2022 Financial Results and Provides Corporate Update

MAIA Biotechnology, Inc. (NYSE American: MAIA) (MAIA, the Company) today announced that it completed a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the planned U.S. expansion of the THIO-101 Phase 2 trial evaluating THIO, an investigational...

MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of MAIA Biotechnology, Inc. (NYSE: MAIA). The in-depth 20-page initiation report includes detailed information on the MAIA ...

Diamond Equity Research Initiates Coverage on MAIA Biotechnology, Inc. (NYSE: MAIA)

Presentation Times and Weblinks Released for Over 35 Presenting CompaniesWednesday and Thursday, November 9-10, 2022NEW YORK, NY / ACCESSWIRE / November 8, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking...

Sidoti's November Micro-Cap Virtual Conference

Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will ...

UPDATE - Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on October 4, 2022

Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will ...

Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on October 4, 2022

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.

Watchers	1,446
52-Wk Low	$0.90
52-Wk High	$5.22

Volume (M)	1,469.00
52-Wk High	$5.22
52-Wk Low	$0.90

Period	Estimated	Reported	Surprise	Result
Q3'23	$-0.39	--	--	N/A
Q2'23	$-0.38	$-0.35	7.89%	BEAT
Q1'23	$-0.40	$-0.38	5.00%	BEAT
Q4'22	$-0.41	$-0.42	-2.41%	MISSED
Q3'22	--	$-0.49	--	N/A

MAIA MAIA Biotechnology Inc

About

Feed

News

Earnings

Fundamentals